Matinas Biopharma (MTNB) Stock Price, News & Analysis

Company Overview

Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company. It engages in the business of delivering groundbreaking therapies using lipid nanocrystal platform delivery technology to maximize global clinical impact and patient access. The company was founded by Herbert J. Conrad and Jerome D. Jabbour in May 2013 and is headquartered in Bedminster, NJ.

Key Stats

• Today's Range: $0.87 to $0.95
• 50-Day Range: $0.56 to $1.04
• 52-Week Range: $0.47 to $9.60
• Volume: 92,990 shs
• Average Volume: 236,091 shs
• Market Capitalization: $4.64 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Hold

Matinas Biopharma Stock Analysis - MarketRank™

Matinas Biopharma scored higher than 22% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Matinas Biopharma.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Matinas Biopharma is -0.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Matinas Biopharma is -0.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Matinas Biopharma has a P/B Ratio of 0.21. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.37% of the float of Matinas Biopharma has been sold short.

Short Interest Ratio / Days to Cover

Matinas Biopharma has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Matinas Biopharma has recently decreased by 29.57%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Matinas Biopharma does not currently pay a dividend.

Dividend Growth

Matinas Biopharma does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.37% of the float of Matinas Biopharma has been sold short.

Short Interest Ratio / Days to Cover

Matinas Biopharma has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Matinas Biopharma has recently decreased by 29.57%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: N/A

News Sentiment

Matinas Biopharma has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Matinas Biopharma this week, compared to 0 articles on an average week.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Matinas Biopharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 4.60% of the stock of Matinas Biopharma is held by insiders.

Percentage Held by Institutions

Only 11.77% of the stock of Matinas Biopharma is held by institutions.

MTNB Stock Analysis - Frequently Asked Questions

How have MTNB shares performed this year?

Matinas Biopharma's stock was trading at $0.51 on January 1st, 2025. Since then, MTNB stock has increased by 79.0% and is now trading at $0.9129.
View the best growth stocks for 2025 here.

How were Matinas Biopharma's earnings last quarter?

Matinas Biopharma Holdings, Inc. (NYSE:MTNB) posted its earnings results on Wednesday, August, 14th. The company reported ($0.02) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.02).

How do I buy shares of Matinas Biopharma?

Shares of MTNB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Matinas Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Matinas Biopharma investors own include AcelRx Pharmaceuticals (ACRX), DURECT (DRRX), Kosmos Energy (KOS), Strongbridge Biopharma (SBBP), Selecta Biosciences (SELB), Acasti Pharma (ACST) and Abeona Therapeutics (ABEO).

Company Calendar

• Last Earnings: 8/14/2024
• Today: 6/20/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSE:MTNB
• Previous Symbol: NYSE:MTNB
• CIK: 1582554
• Web: N/A
• Phone: (908) 484-8805
• Fax: N/A
• Employees: 30
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($3.86)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$22.94 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -123.06%
• Return on Assets: -94.28%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.53
• Quick Ratio: 5.53

Sales & Book Value

• Annual Sales: $1.10 million
• Price / Sales: 4.22
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.43 per share
• Price / Book: 0.21

Miscellaneous

• Outstanding Shares: 5,087,000
• Free Float: 4,599,000
• Market Cap: $4.64 million
• Optionable: N/A
• Beta: 1.28